Antios Therapeutics completed a $25 million oversubscribed Series A financing to develop ATI-2173, an oral drug candidate for treating patients with hepatitis B and potentially coinfected with hepatitis D, according to a press release.
“The next frontier in virology is to cure hepatitis B,” Abel de la Rosa, PhD, co-founder and CEO of Antios, said in the release. “The strong financial support from our investors along with their extensive experience in clinical development and success building innovative companies in the infectious disease field will enable us to accelerate the development of ATI-2173 as a potential backbone of therapy to cure HBV.”
The financing was led by Lumira Ventures and Domain Associates. Other investors included CAM Capital, Delos Capital, Quantum Vista Capital, Fonds de solidarité FTQ, and George Research Alliance Venture Fund.
“The unique mechanism of action combined with liver targeting and the potential for a one pill, once-a-day combination regimen makes ATI-2173 an exciting candidate for development to treat HBV,” Douglas Mayers, MD, co-founder and chief medical officer, said in the release.
Disclosures: de la Rosa and Mayers are employed by Antios